Vaccine News and Research

Latest Vaccine News and Research

Department of Health launches “Immunizations across the Lifespan” campaign

Secretary of Health Everette James today urged all Pennsylvanians to ensure they are fully immunized against vaccine-preventable diseases, noting that August is National Immunization Awareness Month.

31 Jul 2010

FDA announces approval of vaccines for 2010-2011 US influenza season

The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States.

31 Jul 2010

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone Influenza Virus Vaccine is underway in the U.S.

31 Jul 2010

Recent releases in Global Health

A Center for Global Development memo offers suggestions for the U.S. to improve its commitment to policies that benefit poor countries after it ranked 17th out of 22 wealthy in the 2009 Commitment to Development Index. Among a set of 20 recommendations, the authors suggest the U.S. "[i]ncrease foreign aid, especially through such vehicles as the Millennium Challenge Corporation (MCC), which gives to relatively well-governed countries, or a global 'Cash on Delivery' fund that would pay countries after making confirmed progress toward agreed-upon outcomes, thereby reducing the proliferation of aid projects," the authors write(Prieto/Roodman).

31 Jul 2010

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

GlaxoSmithKline announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.

30 Jul 2010

Vaccine scares may do more harm than previously believed to population's 'herd immunity'

Public immunization efforts may be much more sensitive than previously realized to small changes in the perceived costs or risks of vaccination, scientists at Harvard University report this week. In some cases, the spread of vaccine avoidance via social networks can make the difference between a minor, localized outbreak and an epidemic four times as large.

30 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

Chemical compound provides new angle for developing drugs to treat seizures: Study

A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute.

30 Jul 2010

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

This year "India has reported the lowest number of polio cases in [the] January-June period ... in a decade," PTI/ZeeTV reports. Twenty-four cases were detected between January and June this year, compared to 151 in the corresponding 2009 period, and 317 in January-June 2008 (7/29).

30 Jul 2010

PPD expands cGMP laboratory testing services into Wayne

PPD, Inc. today announced it has expanded its cGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States.

30 Jul 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010

Random vaccine distribution prevents spread of disease: Study

The best way to prevent the spread of disease in rural areas may be by targeting select popular hangouts, according to a new study by the Kansas State University EpiCenter research team.The team published "Efficient Mitigation Strategies for Epidemics in Rural Regions" in the July edition of the journal PLoS ONE. The study looks at mitigation strategies based on a contact network model developed using information collected from residents in Clay County, Kan.

30 Jul 2010

Geron second-quarter net loss decreases to $17.0 million

Geron Corporation today reported financial results for the three and six months ended June 30, 2010.

30 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2010.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.

28 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

Department of Health launches “Immunizations across the Lifespan” campaign

FDA announces approval of vaccines for 2010-2011 US influenza season

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

Recent releases in Global Health

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

Vaccine scares may do more harm than previously believed to population's 'herd immunity'

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Chemical compound provides new angle for developing drugs to treat seizures: Study

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

PPD expands cGMP laboratory testing services into Wayne

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Random vaccine distribution prevents spread of disease: Study

Geron second-quarter net loss decreases to $17.0 million

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Etubics enters Phase I trials for next generation vector vaccines

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in